Literature DB >> 8443692

Serum tartrate-resistant acid phosphatase (TRAP) as a biochemical marker of bone remodeling.

H Rico1, L F Villa.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8443692     DOI： 10.1007/bf00308325

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  16 in total

Review 1.  Clinical use of biochemical markers of bone remodeling in osteoporosis.

Authors:  P D Delmas
Journal:  Bone       Date:  1992       Impact factor: 4.398

2.  Studies of intracellular distribution of acid phosphatase 5 in the spleen cells of leukemic reticuloendotheliosis by isopycnic gradient centrifugation.

Authors:  K W Lam; P T Dekker; J Castleman; L T Yam
Journal:  Clin Chim Acta       Date:  1976-07-15       Impact factor: 3.786

3.  Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum: biological variations and reference limits.

Authors:  F Schiele; Y Artur; A Y Floc'h; G Siest
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

4.  Immunological and biochemical evidence for identity of tartrate-resistant isoenzymes of acid phosphatases from human serum and tissues.

Authors:  K W Lam; P Lee; C Y Li; L T Yam
Journal:  Clin Chem       Date:  1980-03       Impact factor: 8.327

5.  Tartrate-resistant (band 5) acid phosphatase activity measured by electrophoresis on acrylamide gel.

Authors:  W K Lam; L C Lai; L T Yam
Journal:  Clin Chem       Date:  1978-02       Impact factor: 8.327

6.  [Biological profile of tartrate-resistant acid phosphatase as a marker of bone resorption].

Authors:  H Rico; M Iritia; I Arribas; M Revilla
Journal:  Rev Esp Fisiol       Date:  1990-12

7.  Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase.

Authors:  M E Kraenzlin; K H Lau; L Liang; T K Freeman; F R Singer; J Stepan; D J Baylink
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

8.  Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover.

Authors:  L Scarnecchia; S Minisola; M T Pacitti; V Carnevale; E Romagnoli; R Rosso; G F Mazzuoli
Journal:  Scand J Clin Lab Invest       Date:  1991-10       Impact factor: 1.713

9.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.

Authors:  D R Eyre; T J Koob; K P Van Ness
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

10.  Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.

Authors:  D Uebelhart; A Schlemmer; J S Johansen; E Gineyts; C Christiansen; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958
View more
  12 in total

Review 1.  Acid phosphatases.

Authors:  H Bull; P G Murray; D Thomas; A M Fraser; P N Nelson
Journal:  Mol Pathol       Date:  2002-04

2.  Vertebral and metacarpal morphometry as indicators of nutritional improvement.

Authors:  M Revilla; E Fraile; F Aguado; E R Hermandez; L F Villa; H Rico
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

3.  Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry.

Authors:  P Ballanti; S Minisola; M T Pacitti; L Scarnecchia; R Rosso; G F Mazzuoli; E Bonucci
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  Ultrasound bone mass in patients undergoing chronic therapy with oral anticoagulants.

Authors:  Purificacion Rey-Sanchez; Jesus Maria Lavado-Garcia; Maria Luz Canal-Macias; Maria Trinidad Rodriguez-Dominguez; Jose Luis Bote-Mohedano; Juan Diego Pedrera-Zamorano
Journal:  J Bone Miner Metab       Date:  2011-01-14       Impact factor: 2.626

5.  Influence of estrogen deficiency on bone around osseointegrated dental implants: an experimental study in the rat jaw model.

Authors:  Gabriela Giro; Paulo G Coelho; Roberto Sales-Pessoa; Rosa Maria Rodrigues Pereira; Toshihisa Kawai; Silvana Regina Perez Orrico
Journal:  J Oral Maxillofac Surg       Date:  2011-04-29       Impact factor: 1.895

6.  Beta-2-microglobulin in diseases with high bone remodeling.

Authors:  E Ripoll; I Arribas; P Relea; L Varela; L F Villa; M Revilla; H Rico
Journal:  Calcif Tissue Int       Date:  1995-10       Impact factor: 4.333

7.  Possible antiosteoporotic mechanism of Cicer arietinum extract in ovariectomized rats.

Authors:  Sohair R Fahmy; Amel M Soliman; Amany A Sayed; Mohamed Marzouk
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

8.  Bone mass in Parkinson's disease: a study with three methods.

Authors:  M Revilla; G de la Sierra; F Aguado; L Varela; F J Jiménez-Jiménez; H Rico
Journal:  Calcif Tissue Int       Date:  1996-05       Impact factor: 4.333

9.  Beta 2-microglobulin in postmenopausal osteoporosis.

Authors:  H Rico; E Ripoll; M Revilla; P Relea; L F Villa
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

10.  beta 2-Microglobulin in Paget's bone disease.

Authors:  H Rico; E Ripoll; I Arribas; M Revilla; P Relea; L F Villa; M A de Buergo
Journal:  Calcif Tissue Int       Date:  1994-05       Impact factor: 4.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.